Additionally, in a cohort of pembrolizumab-treated breast cancer patients, the relative frequency of mregDCs positively correlated with T-cell expansion following anti-PD-1 treatment, and mregDCs supported T-cell function in responders at baseline and during treatment40. Here, PDCD1 is linked to breast cancer.